Evidence map›Paper›PMID 22658484›Full record

ArticleThe American journal of pathology2012

Prolactin promotes mammary pathogenesis independently from cyclin D1.

Jennifer M Asher, Kathleen A O'Leary, Debra E Rugowski, Lisa M Arendt, Linda A Schuler

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jennifer M AsherDepartment of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
Kathleen A O'Leary
Debra E Rugowski
Lisa M Arendt
Linda A Schuler
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
WOMEN'S HEALTH AND AGING: RESEARCH &LEADERSHIP TRAININGT32AG000265 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CARNES, MOLLY L. · 1999 to 2008
$2.2M
MAMMARY PROLACTIN PRODUCTION AND BREAST CANCERR01CA078312 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI SCHULER, LINDA A. · 1999 to 2005
$1.3M
Short-Term Research Training of Veterinary Students in WisconsinT35OD011078 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI BJORLING, DALE EDMOND, JORGENSEN, JOAN S · 2012 to 2025
$1.0M
RESEARCH TRAINING OF VETERINARY STUDENTS IN WISCONSINT32RR017503 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI BJORLING, DALE EDMOND · 2003 to 2011
$774k
Interactions of PRL, Estrogen, and TFFa in Mammary CancerK01RR021858 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI ARENDT, LISA M · 2006 to 2010
$564k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA078312NCI NIH HHS R01 CA78312NCRR NIH HHS K01 RR021858NCRR NIH HHS T32 RR017503NIA NIH HHS T32 AG000265NIA NIH HHS T32 AG00265NIH HHS T35 OD011078
6 · The paper itself

Abstract

Epidemiological and experimental studies have revealed an important role for prolactin (PRL) in breast cancer. Cyclin D1 is a major downstream target of PRL in lobuloalveolar development during pregnancy and is amplified and/or overexpressed in many breast carcinomas. To examine the importance of cyclin D1 in PRL-induced pathogenesis, we generated transgenic mice (NRL-PRL) that overexpress PRL in mammary epithelial cells, with wild-type, heterozygous, or genetically ablated cyclin D1 in the FVB/N genetic background. Although loss of one cyclin D1 allele did not affect PRL-induced mammary lesions in nonparous females, the complete absence of cyclin D1 (D1(-/-)) markedly decreased tumor incidence. Nevertheless, NRL-PRL/D1(-/-) females developed significantly more preneoplastic lesions (eg, epithelial hyperplasias and mammary intraepithelial neoplasias) than D1(-/-) females. Moreover, although lack of cyclin D1 reduced proliferation of morphologically normal mammary epithelium, transgenic PRL restored it to rates of wild-type females. PRL posttranscriptionally increased nuclear cyclin D3 protein in D1(-/-) luminal cells, indicating one compensatory mechanism. Consistently, pregnancy induced extensive lobuloalveolar growth in the absence of cyclin D1. However, transcripts for milk proteins were reduced, and pups failed to survive, suggesting that mammary differentiation was inadequate. Together, these results indicate that cyclin D1 is an important, but not essential, mediator of PRL-induced mammary proliferation and pathology in FVB/N mice and is critical for differentiation and lactation.

Indexed as

AdenocarcinomaAnimalsCell ProliferationCell Transformation, NeoplasticCyclin D1Cyclin D3EstradiolEstrogen Receptor alphaFemaleLactationMammary Glands, AnimalMammary Neoplasms, ExperimentalMiceMice, TransgenicNeoplasm ProteinsPrecancerous ConditionsCcnd1 protein, mouseCcnd3 protein, mouseCyclin D1Cyclin D3EstradiolEstrogen Receptor alphaNeoplasm ProteinsProlactin

Identifiers

PMID22658484
PMCPMC3388158
OpenAlexW2091275889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.